A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus (RSV), Infectious Disease
In brief
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
Key facts
- Study ID
- NCT06564194
- Run by
- Immorna Biotherapeutics, Inc.
- People needed
- 75
- Starts
- 2024-09-25
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2026-04-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Health Awareness — Jupiter, Florida, United States
- DelRicht - New Orleans — New Orleans, Louisiana, United States
- Sundance Clinical Research — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.